← Back to patent-cliff list
CAS 2413947-55-2
(3S,4aR,6R,11S,12aS)-3-Bromo-9,12a,13,13-tetramethyl-11-[(triethylsilyl)oxy]-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione
Codes: (XVIII)101438-68-a
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3S,4aR,6R,11S,12aS)-3-Bromo-9,12a,13,13-tetramethyl-11-[(triethylsilyl)oxy]-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(3S,4aR,6R,12aR)-3-Bromo-9,12a,13,13-tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,11S,12aS)-9,12a,13,13-Tetramethyl-11-[(triethylsilyl)oxy]-4a,6,7,11,12,12a-hexahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→1,1-Dibromo-2,2,3,3-tetramethylcyclopropane→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,6,7,8,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5(1H,4aH)-dione→(Vinyl)magnesium bromide→1,1,2,2-Tetramethylethylene→2-Hydroxy-2-methylbutanoic acid→2-Propen-1-one→3-(3-Isopropenyl-4-methyl-3-pentenyl)-2-cyclohexen-1-one→3-Bromo-2,4-dimethylpenta-1,3-diene→3-Ethenylcyclohex-2-en-1-one→3-Ethoxy-2-cyclohexen-1-one→Aluminum trimethanide→Methylmagnesium bromide→Bromoform→Trimethyl([(3S)-3-methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]cyclohex-1-en-1-yl]oxy)silane→(2beta,4alpha,10beta,13alpha)-10-[(Triethylsilyl)oxy](2-~2~H)taxa-5,11-diene-2,4,13-triol→(2S,3S)-2,3-Dimethyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one→(2S,3S)-3-Methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one
(3S,4aR,6R,11S,12aS)-3-Bromo-9,12a,13,13-tetramethyl-11-[(triethylsilyl)oxy]-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(3S,4aR,6R,12aR)-3-Bromo-9,12a,13,13-tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,11S,12aS)-9,12a,13,13-Tetramethyl-11-[(triethylsilyl)oxy]-4a,6,7,11,12,12a-hexahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,4a,6,7,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5,8(1H)-trione→1,1-Dibromo-2,2,3,3-tetramethylcyclopropane→(4aS,6R,12aS)-9,12a,13,13-Tetramethyl-2,3,6,7,8,11,12,12a-octahydro-6,10-methanobenzo[10]annulene-4,5(1H,4aH)-dione→(Vinyl)magnesium bromide→1,1,2,2-Tetramethylethylene→2-Hydroxy-2-methylbutanoic acid→2-Propen-1-one→3-(3-Isopropenyl-4-methyl-3-pentenyl)-2-cyclohexen-1-one→3-Bromo-2,4-dimethylpenta-1,3-diene→3-Ethenylcyclohex-2-en-1-one→3-Ethoxy-2-cyclohexen-1-one→Aluminum trimethanide→Methylmagnesium bromide→Bromoform→Trimethyl([(3S)-3-methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]cyclohex-1-en-1-yl]oxy)silane→(2beta,4alpha,10beta,13alpha)-10-[(Triethylsilyl)oxy](2-~2~H)taxa-5,11-diene-2,4,13-triol→(2S,3S)-2,3-Dimethyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one→(2S,3S)-3-Methyl-3-[4-methyl-3-(prop-1-en-2-yl)pent-3-en-1-yl]-2-(prop-2-enoyl)cyclohexan-1-one
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.